Evoke Pharma Inc
NASDAQ:EVOK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.07
24.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Evoke Pharma Inc
Cash from Operating Activities
Evoke Pharma Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Evoke Pharma Inc
NASDAQ:EVOK
|
Cash from Operating Activities
-$3.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$24.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$16.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
25%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$13.1B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$17.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$16.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
17%
|
|
Evoke Pharma Inc
Glance View
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 4 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. Evoke is developing its product Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Gimoti, is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a formulation of metoclopramide offering systemic delivery by nasal spray administration.
See Also
What is Evoke Pharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-3.3m
USD
Based on the financial report for Sep 30, 2025, Evoke Pharma Inc's Cash from Operating Activities amounts to -3.3m USD.
What is Evoke Pharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
11%
Over the last year, the Cash from Operating Activities growth was 38%. The average annual Cash from Operating Activities growth rates for Evoke Pharma Inc have been 18% over the past three years , 11% over the past five years , and 11% over the past ten years .